Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy
- PMID: 8077068
- DOI: 10.1016/0167-5273(94)90286-0
Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy
Abstract
The history of an 18-year-old male with hypertrophic cardiomyopathy (HCM) and ventricular dilatation is presented and the literature on systolic dysfunction and ventricular dilatation in patients with HCM is statistically analyzed in search of risk factors. The patient was followed for 7 years when he developed recurrent ventricular fibrillation, left ventricular dilatation and low cardiac output. An automatic cardioverter-defibrillator was implanted but the patient died of electro-mechanical dissociation. In order to define risk factors for systolic dysfunction and ventricular dilatation in HCM, the literature data of 17 patients with this complication were compared to a group of 139 consecutive patients with HCM from our hospital. The risk factors identified were a more markedly increased septal (20.1 vs. 18.0 mm, P < 0.05) and posterior wall thickness (13.6 vs. 11.0 mm, P < 0.001) in the patients subsequently developing systolic dysfunction and ventricular dilatation, whereas age, sex and the ratio between septal and posterior wall thickness were not significantly different between the two groups. A severely increased ventricular mass appears to be a risk factor for the development of systolic dysfunction with ventricular dilatation in HCM. Prognosis is usually poor and the reported case showed fatal ventricular arrhythmia despite the implantation of an automatic cardioverter-defibrillator.
Similar articles
-
Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.Heart Vessels. 2018 Jan;33(1):49-57. doi: 10.1007/s00380-017-1030-3. Epub 2017 Aug 1. Heart Vessels. 2018. PMID: 28766047
-
Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy.Br Heart J. 1995 Nov;74(5):508-16. doi: 10.1136/hrt.74.5.508. Br Heart J. 1995. PMID: 8562235 Free PMC article.
-
Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.JAMA. 2007 Jul 25;298(4):405-12. doi: 10.1001/jama.298.4.405. JAMA. 2007. PMID: 17652294
-
Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.Eur Heart J. 2017 Jun 7;38(22):1728-1737. doi: 10.1093/eurheartj/ehw268. Eur Heart J. 2017. PMID: 27371714 Review.
-
[Malignant form of familial hypertrophic cardiomyopathy complicated with ventricular fibrillation in siblings. Electrocardiogram in hypertrophic cardiomyopathy - a review].Kardiol Pol. 2009 Jul;67(7):774-80; discussion 781. Kardiol Pol. 2009. PMID: 19650001 Review. Polish.
Cited by
-
Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy.Int J Cardiovasc Imaging. 2003 Dec;19(6):499-510. doi: 10.1023/b:caim.0000004262.48898.5d. Int J Cardiovasc Imaging. 2003. PMID: 14690189
-
ELAC2/RNaseZ-linked cardiac hypertrophy in Drosophila melanogaster.Dis Model Mech. 2021 Aug 1;14(8):dmm048931. doi: 10.1242/dmm.048931. Epub 2021 Aug 31. Dis Model Mech. 2021. PMID: 34338278 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources